Search

Your search keyword '"Trevisini, Sara"' showing total 5 results
Start Over Author "Trevisini, Sara" Language undetermined
5 results on '"Trevisini, Sara"'

1. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Author

Costanzo, Antonio, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Scuderi, Roberta, Zichichi, Leonardo, Papini, Manuela, Di Costanzo, Luisa, Conti, Andrea, Burlando, Martina, Chiricozzi, Andrea, Gaiani, Francesca Maria, Mugheddu, Cristina, Musumeci, Maria Letizia, Gisondi, Paolo, Piaserico, Stefano, Dapavo, Paolo, Venturini, Marina, Pagnanelli, Gianluca, Amerio, Paolo, Potenza, Concetta, Peris, Ketty, Cantoresi, Franca, Trevisini, Sara, Loconsole, Francesco, Offidani, Annamaria, Mercuri, Santo Raffaele, Lora, Viviana, Prignano, Francesca, Bartezaghi, Marta, Oliva, Giovanni, Aloisi, Elisabetta, Orsenigo, Roberto, Supreme study group, Matteo, Megna, Antonio, Costanzo, Filomena, Russo, Marco, Galluzzo, Luca, Stingeni, Roberta, Scuderi, Leonardo, Zichichi, Manuela, Papini, Luisa, Di Costanzo, Andrea, Conti, Martina, Burlando, Andrea, Chiricozzi, Francesca Maria, Gaiani, Cristina, Mugheddu, Maria Letizia, Musumeci, Paolo, Gisondi, Stefano, Piaserico, Paolo, Dapavo, Marina, Venturini, Gianluca, Pagnanelli, Paolo, Amerio, Concetta, Potenza, Ketty, Peri, Franca, Cantoresi, Sara, Trevisini, Francesco, Loconsole, Annamaria, Offidani, Santo Raffaele, Mercuri, Viviana, Lora, Francesca, Prignano, Marta, Bartezaghi, Giovanni, Oliva, Elisabetta, Aloisi, Roberto, Orsenigo, study group, Supreme, and Megna, Matteo

Subjects
medicine.medical_specialty, Psoriasis, secukinumab, PASI 90, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, interleukin-17A, Settore MED/35, Psoriasis Area and Severity Index, Psoriasis, Humans, Medicine, In patient, Plaque psoriasis, business.industry, secukinumab, Moderate to severe psoriasis, psoriasis, General Medicine, medicine.disease, humanities, Treatment Outcome, RL1-803, Secukinumab, Interleukin 17, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Published
2021

2. Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic

Author

Sara Trevisini, Giusto Trevisan, Iris Zalaudek, Serena Bonin, Trevisini, Sara, Trevisan, Giusto, Zalaudek, Iri, and Bonin, Serena

Subjects
therapy, TNF alpha inhibitor, Adamantiades-Behçet's disease, COVID, TNF alpha inhibitors, SARS-CoV-2, Behcet Syndrome, Dermatology, General Medicine, Etanercept, COVID-19 Drug Treatment, Humans, Pandemics
Abstract

Adamantiades-Behçet's disease (ABD) is a chronic, idiopathic, relapsing immune-mediate disease that may involve multiple organs. It is characterized by recurrent oral and genital ulcers, skin lesions, ocular, gastrointestinal, vascular, neurological and joint involvement. It can lead to significant morbidity and mortality. Due to its heterogeneity in clinical findings and physiopathology, its treatment can be various as ABD manifestations in different organs may differently respond to the same drug. The cornerstone of therapy for inducing remission is systemic corticosteroid, whereas immunomodulatory and immunosuppressive agents such as colchicine, azathioprine, cyclosporine-A, interferon-alpha, and cyclophosphamide are used as steroid-sparing agents and to prevent relapses. For aggressive, refractory or frequently relapsing cases, tumor necrosis factor (TNF) alpha inhibitors (infliximab, adalimumab, etanercept) have been reported beneficial. Herein, we describe our experience of 7 patients treated with TNF-alpha inhibitors with recommendations regarding treatment choice during the COVID-19 era.

Published
2021

3. Polypoid and fungating form of elephantiasic pretibial myxedema with involvement of the hands

Author

Nicola di Meo, Giusto Trevisan, Mattia Fadel, Giovanni Damiani, Katiuscia Nan, Sara Trevisini, Silvia Vichi, Cecilia Noal, DI MEO, Nicola, Nan, Katiuscia, Noal, Cecilia, Trevisini, Sara, Fadel, Mattia, Damiani, Giovanni, Vichi, Silvia, and Trevisan, Giusto

Subjects
medicine.medical_specialty, Leg Dermatosis, Hand Dermatose, Graves' disease, Hand Dermatoses, Dermatology, Leg Dermatoses, Elephantiasic pretibial myxedema, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Hand Dermatosis, Myxedema, medicine, Humans, business.industry, Middle Aged, medicine.disease, Graves Disease, Surgery, Leg Dermatose, 030220 oncology & carcinogenesis, Female, 2708, business, Human
Abstract

NONE

Published
2016

4. Abdominopelvic post-irradiation morphea in a prostate cancer patient: the first case of an under-recognized condition

Author

Giusto Trevisan, di Meo N, Cecilia Noal, Bruno Ulessi, Sara Trevisini, DI MEO, Nicola, Noal, Cecilia, Trevisini, Sara, Ulessi, B., and Trevisan, Giusto

Subjects
medicine.medical_specialty, business.industry, General surgery, Dermatology, MORPHEA, PROSTATE CANCER, Thigh, medicine.disease, Prostate cancer, Infectious Diseases, medicine.anatomical_structure, Text mining, medicine, Abdomen, Radiodermatitis, Radiology, Differential diagnosis, business, Pelvis, Morphea
Abstract

NONE

Published
2015

5. Sporotrichoid Mycobacterium marinum infection in an elderly woman

Author

Sara Trevisini, Giusto Trevisan, Nicola di Meo, Antonio Albano, Sergio Umberto De Marchi, Giuseppe Stinco, DI MEO, Nicola, Stinco, Giuseppe, Trevisini, Sara, DE MARCHI, SERGIO UMBERTO, Albano, Antonio, and Trevisan, Giusto

Subjects
Mycobacterium marinum sporotrichoid nodules, medicine.medical_specialty, Mycobacterium Infections, Nontuberculous, Dermatology, Diagnosis, Differential, Clarithromycin, Mycobacterium marinum Infection, medicine, Animals, Humans, Mycobacterium marinum, Skin, Aged, 80 and over, Distal forearm, Doxycycline, integumentary system, biology, business.industry, Skin exposure, Fishes, General Medicine, bacterial infections and mycoses, biology.organism_classification, Anti-Bacterial Agents, Surgery, Regimen, Drug Therapy, Combination, Female, Rifampin, business, Rifampicin, medicine.drug
Abstract

We describe the case of an elderly woman who acquired a Mycobacterium marinum infection following skin exposure to the bacteria through a small wound on her right ring finger, obtained while preparing fish. The resultant sporotrichoid nodules of the right hand and the distal forearm, refractory to the initial therapy with doxycycline and rifampicin, were successfully treated with oral regimen of clarithromycin.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results